S
Sandra Rost
Researcher at Genentech
Publications - 12
Citations - 4473
Sandra Rost is an academic researcher from Genentech. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 6, co-authored 10 publications receiving 3656 citations.
Papers
More filters
Journal ArticleDOI
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst,Jean-Charles Soria,Marcin Kowanetz,Gregg Fine,Omid Hamid,Michael S. Gordon,J. A. Sosman,David F. McDermott,John D. Powderly,Scott N. Gettinger,Holbrook E Kohrt,Leora Horn,Donald P. Lawrence,Sandra Rost,Maya Leabman,Yuanyuan Xiao,Ahmad Mokatrin,Hartmut Koeppen,Priti S. Hegde,Ira Mellman,Daniel S. Chen,F. Stephen Hodi +21 more
TL;DR: Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types.
Journal ArticleDOI
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
Bharathi Vennapusa,Brian Baker,Marcin Kowanetz,Jennifer Boone,Ina Menzl,Jean-Marie Bruey,Gregg Fine,Sanjeev Mariathasan,Ian McCaffery,Simonetta Mocci,Sandra Rost,Dustin Smith,Eslie Dennis,Szu-Yu Tang,Bita Damadzadeh,Espen Walker,Priti S. Hegde,J. Andrew Williams,Hartmut Koeppen,Zachary Boyd +19 more
TL;DR: A diagnostic assay that measures programmed-death ligand 1 (PD-L1) expression, via immunohistochemistry, to identify patients who will derive the most benefit from treatment with atezolizumab, a humanized monoclonal anti-PD- L1 antibody is described.
Journal ArticleDOI
Developing biomarkers to predict benefit from HGF/MET pathway inhibitors
TL;DR: The current knowledge of mechanisms of MET activation, the status of the clinical evaluation of MET‐targeted therapies, the associated efforts to identify and validate biomarkers, and the considerations and challenges for potential development of companion diagnostics are discussed.
Journal ArticleDOI
Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections
Sandra Rost,Jennifer M. Giltnane,Jennifer Bordeaux,Chuck Hitzman,Hartmut Koeppen,Scot D. Liu +5 more
TL;DR: Using HER2 as a model, data show MIBI analysis can quantitate protein expression with greater sensitivity and objectivity compared to standard pathologist interpretation, demonstrating its potential as a technology capable of advancing cancer and patient diagnostics.
Journal ArticleDOI
Clinical and research applications of multiplexed immunohistochemistry and in situ hybridization
TL;DR: A review of the technical features, advantages, and limitations of currently available multiplexed immunohistochemistry and spatial transcriptomic platforms can be found in this paper, with a focus on RNA and protein expression profiles in the same sample.